資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSELSEVIERIHS_EWB_GF

頁面路徑選單

Global Hyaluronic Acid Market Research Report—Forecast till 2025

  • LinkedIn
  • facebook
  • Twitter
出版日期:2020/12/01
頁  數:179頁
文件格式:PDF
價  格:
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
線上訂購或諮詢
Global Hyaluronic Acid Market: Information by Grade (Cosmetic Grade, Pharmaceutical Grade and Food Grade), By Application (Aesthetics, Osteoarthritis, Pharmaceutical API, Cosmetics, Dietary Supplements, Ophthalmology and Others), By End User (Pharmaceutical Industry, Dermatology Clinics & Cosmetic Surgery Centers, Food Industry, Personal Care and Others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Analysis
Hyaluronic Acid Market is expected to register a CAGR of 7.02% to reach USD 18,153.6 Million by the year 2025. Hyaluronic acid is a glycosaminoglycan polymer commonly found in the extracellular matrix of vertebrate epithelial, connective, and neural tissues. It plays an important role in the many signaling pathways in the human body and useful in the treatment of joint and eye disorders, as well as plastic surgeries. Demand for a hyaluronic acid is increasing due to the increasing application of hyaluronic acid in cosmetic & personal care products and the increasing number of cosmetic surgeries. These factors are expected to fuel the growth of the global hyaluronic acid market. However, the availability of substitutes is expected to hinder market growth. Dermatologists inject hyaluronic acid-based fillers to make the skin appear firm. Botox and dermal filler treatments are popular, accounting for more than 9 million procedures in 2015, according to the American Society of Plastic Surgeons (ASPS). The use of hyaluronic acid dermal fillers is approved by the Food and Drug Administration (FDA). According to the International Society of Aesthetic Plastic Surgery (ISAPS), 465,296 modernization surgeries were performed in 2017, which grew by 9% in 2018. It is also used as a lip filler in plastic surgeries. According to the annual plastic surgery procedural statistics, there were 17.5 million surgical and minimally invasive cosmetic procedures performed in the US in the year 2017, a 2% increase over the year 2016. As per the American Society for Aesthetic Plastic Surgery (ASAPS), the use of hyaluronic acid injections increased by 58.4% in 2018, as compared to 2014. The organization also states that hyaluronic acid treatment was the second-leading non-surgical cosmetic procedure in 2018. Estimates that 810,240 hyaluronic acid procedures performed in 2018, after botulinum toxin in the Americas, with a outlay of nearly USD 544 million.

Market Segmentation
Global Hyaluronic Acid Market has been segmented by Grade, by Application, by End User and by End User. Based on Grade the Global Hyaluronic Acid Market has been segmented into cosmetic Grade, Pharmaceutical Grade and Food Grade. Based on Application the market has been segmented into Aesthetics, Osteoarthritis, Pharmaceutical API, Cosmetics, Dietary Supplements, Ophthalmology and Others. Based on End User the Global Hyaluronic Acid Market has been segmented into Pharmaceutical Industry, Dermatology Clinics & Cosmetic Surgery Centers, Food Industry, Personal Care and Others. The dermatology clinics & cosmetic surgery centers held a share of 23.2% in the year 2018. Geographically the Global Hyaluronic Acid Market has been segmented into various different regions like Americas, Europe, Asia-Pacific, Middle East & Africa. Americas is sub- segmented into North America (US & Canada) and Latin America, Europe is sub-segmented into Western Europe (Germany, UK, France, Italy, Spain and Rest of Western Europe) and Eastern Europe. Asia-Pacific is sub-segmented into Japan, China, India, Australia, South Korea and Rest of Asia-Pacific, Middle East & Africa.

Regional Analysis
The global hyaluronic acid market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global hyaluronic acid market. The growth in this region may be attributed to high demand for the product in the pharmaceutical industry. For example, the availability of a large pharmaceutical base in the US is a vital driver for the growth of the regional market. According to the European Federation of Pharmaceutical Industries & Association (EFPIA), North America accounted for 48.9% of world pharmaceutical sales in 2017. Moreover, the US invested nearly USD 55,755 million in pharmaceutical R&D expenditure, which exhibited an annual growth rate of 8.6%. Additionally, many important companies in the market are developing regional vendors to strengthen its position in the market. Europe held a share of 26.8% in the global hyaluronic acid market in 2018. This can be attributed to the increasing application of hyaluronic acid in cosmetic & personal care products. Asia-Pacific are estimated being the fastest-growing region in the global market. This is due to growing demand for hyaluronic acid and a growing number of cosmetic surgeries fueling the growth of the hyaluronic acid market in the region. The hyaluronic acid market in the Middle East & Africa is expected to witness steady growth during the review period due to limited access and healthcare affordability among the population. Growing awareness of hyaluronic acid is expected to drive market growth during the assessment period.

Major Players
Pharmaceutical companies, Contract research manufacturing organizations, Research & development organizations and Academic institutes are some of the projected on lookers for the Global Hyaluronic Acid Market. Allergan, Contipro AS, Symatese Group, Zhonglan Industry Co., Ltd, Altergon Italia SRL, Fidia Farmaceutici SPA, Bioiberica SAU, Kewpie Corporation, Seikagaku Corporation, and Anika Therapeutics are some of the major players in the Global Hyaluronic Acid Market are

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVE ANALYSIS 19

1.1.1 GLOBAL HYALURONIC ACID MARKET, BY GRADE 19

1.1.2 GLOBAL HYALURONIC ACID, BY APPLICATION 20

1.1.3 GLOBAL HYALURONIC ACID, BY END USER 21

2 MARKET INTRODUCTION
2.1 DEFINITION 22

2.2 SCOPE OF THE STUDY 22

2.3 MARKET STRUCTURE 22

3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 23

3.2 PRIMARY RESEARCH 24

3.3 SECONDARY RESEARCH 25

3.4 MARKET SIZE ESTIMATION 26

3.5 FORECAST MODEL 27

3.6 LIST OF ASSUMPTIONS 27

4 MARKET DYNAMICS
4.1 INTRODUCTION 28

4.2 DRIVERS 29

4.2.1 INCREASING APPLICATION OF HYALURONIC ACID IN COSMETIC & PERSONAL CARE PRODUCTS 29

4.2.2 INCREASING NUMBER OF COSMETIC SURGERIES 30

4.2.3 EXTENSIVE USE OF HYALURONIC ACID IN THE TREATMENT OF OSTEOARTHRITIS AND DRY EYE 31

4.3 RESTRAINTS 32

4.3.1 AVAILABILITY OF SUBSTITUTES 32

4.4 OPPORTUNITY 33

4.4.1 EXTENSIVE RESEARCH AND DEVELOPMENT ASSOCIATED WITH HYALURONIC ACID 33

4.5 TREND 34

4.5.1 USE OF HYALURONIC ACID AS AN ANIMAL SUPPLEMENT 34

5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS 35

5.1.1 RAW MATERIAL SUPPLIERS 35

5.1.2 HYALURONIC ACID PRODUCERS 36

5.1.3 DISTRIBUTION & SALES CHANNEL 36

5.1.4 END USERS 36

5.2 PORTER’S FIVE FORCES MODEL 37

5.2.1 THREAT OF NEW ENTRANTS 37

5.2.2 INTENSITY OF RIVALRY 38

5.2.3 THREAT OF SUBSTITUTES 38

5.2.4 BARGAINING POWER OF SUPPLIERS 38

5.2.5 BARGAINING POWER OF BUYERS 38

6 GLOBAL HYALURONIC ACID MARKET, BY GRADE
6.1 OVERVIEW 39

6.2 COSMETIC GRADE 41

6.3 PHARMACEUTICAL GRADE 41

6.4 FOOD GRADE 42

7 GLOBAL HYALURONIC ACID MARKET, BY APPLICATION
7.1 OVERVIEW 43

7.2 AESTHETICS 44

7.3 OSTEOARTHRITIS 45

7.4 PHARMACEUTICAL API 46

7.5 COSMETICS 46

7.6 DIETARY SUPPLEMENTS 47

7.7 OPHTHALMOLOGY 48

7.8 OTHERS 48

8 GLOBAL HYALURONIC ACID MARKET, BY END USER
8.1 OVERVIEW 49

8.2 PHARMACEUTICAL INDUSTRY 51

8.3 DERMATOLOGY CLINICS & COSMETIC SURGERY CENTERS 52

8.4 FOOD INDUSTRY 52

8.5 PERSONAL CARE 53

8.6 OTHERS 53

9 GLOBAL HYALURONIC ACID MARKET, BY REGION
9.1 OVERVIEW 54

9.2 NORTH AMERICA 57

9.2.1 US 61

9.2.2 CANADA 63

9.3 EUROPE 66

9.3.1 FRANCE 70

9.3.2 GERMANY 73

9.3.3 UK 75

9.3.4 SPAIN 78

9.3.5 ITALY 80

9.3.6 RUSSIA 83

9.3.7 BELGIUM 85

9.3.8 POLAND 88

9.3.9 REST OF EUROPE 90

9.4 ASIA-PACIFIC 93

9.4.1 CHINA 97

9.4.2 JAPAN 100

9.4.3 INDIA 102

9.4.4 SOUTH KOREA 105

9.4.5 AUSTRALIA 107

9.4.6 THAILAND 110

9.4.7 INDONESIA 112

9.4.8 REST OF ASIA-PACIFIC 115

9.5 LATIN AMERICA 118

9.5.1 BRAZIL 122

9.5.2 MEXICO 125

9.5.3 ARGENTINA 127

9.5.4 REST OF LATIN AMERICA 130

9.6 MIDDLE EAST & AFRICA 133

9.6.1 SAUDI ARABIA 137

9.6.2 UAE 140

9.6.3 TURKEY 142

9.6.4 SOUTH AFRICA 145

9.6.5 ISRAEL 147

9.6.6 REST OF MIDDLE EAST AND AFRICA 150

10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW 153

10.2 GLOBAL MARKET STRATEGY ANALYSIS 153

10.3 KEY DEVELOPMENTS 153

10.4 COMPETITIVE BENCHMARKING 154

11 COMPANY PROFILES
11.1 ALLERGAN 155

11.1.1 COMPANY OVERVIEW 155

11.1.2 FINANCIAL OVERVIEW 156

11.1.3 PRODUCTS OFFERED 156

11.1.4 KEY DEVELOPMENTS 157

11.1.5 SWOT ANALYSIS 157

11.1.6 KEY STRATEGIES 157

11.2 CONTIPRO A.S. 158

11.2.1 COMPANY OVERVIEW 158

11.2.2 FINANCIAL OVERVIEW 158

11.2.3 PRODUCTS OFFERED 158

11.2.4 KEY DEVELOPMENTS 158

11.2.5 SWOT ANALYSIS 159

11.2.6 KEY STRATEGIES 159

11.3 SYMATESE GROUP 160

11.3.1 COMPANY OVERVIEW 160

11.3.2 FINANCIAL OVERVIEW 160

11.3.3 PRODUCTS OFFERED 160

11.3.4 KEY DEVELOPMENTS 160

11.3.5 SWOT ANALYSIS 161

11.3.6 KEY STRATEGIES 161

11.4 ZHONGLAN INDUSTRY CO., LTD 162

11.4.1 COMPANY OVERVIEW 162

11.4.2 FINANCIAL OVERVIEW 162

11.4.3 PRODUCTS OFFERED 162

11.4.4 KEY DEVELOPMENTS 162

11.4.5 SWOT ANALYSIS 163

11.4.6 KEY STRATEGIES 163

11.5 ALTERGON ITALIA SRL 164

11.5.1 COMPANY OVERVIEW 164

11.5.2 FINANCIAL OVERVIEW 164

11.5.3 PRODUCTS OFFERED 164

11.5.4 KEY DEVELOPMENTS 164

11.5.5 SWOT ANALYSIS 165

11.5.6 KEY STRATEGIES 165

11.6 FIDIA FARMACEUTICI S.P.A. 166

11.6.1 COMPANY OVERVIEW 166

11.6.2 FINANCIAL OVERVIEW 166

11.6.3 PRODUCTS OFFERED 166

11.6.4 KEY DEVELOPMENTS 166

11.6.5 SWOT ANALYSIS 167

11.6.6 KEY STRATEGIES 167

11.7 BIOIBERICA S.A.U. 168

11.7.1 COMPANY OVERVIEW 168

11.7.2 FINANCIAL OVERVIEW 168

11.7.3 PRODUCTS OFFERED 168

11.7.4 KEY DEVELOPMENTS 168

11.7.5 SWOT ANALYSIS 169

11.7.6 KEY STRATEGIES 169

11.8 KEWPIE CORPORATION 170

11.8.1 COMPANY OVERVIEW 170

11.8.2 FINANCIAL OVERVIEW 170

11.8.3 PRODUCTS OFFERED 171

11.8.4 KEY DEVELOPMENTS 171

11.8.5 SWOT ANALYSIS 171

11.8.6 KEY STRATEGIES 171

11.9 SEIKAGAKU CORPORATION 172

11.9.1 COMPANY OVERVIEW 172

11.9.2 FINANCIAL OVERVIEW 173

11.9.3 PRODUCTS OFFERED 173

11.9.4 KEY DEVELOPMENTS 174

11.9.5 SWOT ANALYSIS 174

11.9.6 KEY STRATEGIES 174

11.10 ANIKA THERAPEUTICS 175

11.10.1 COMPANY OVERVIEW 175

11.10.2 FINANCIAL OVERVIEW 175

11.10.3 PRODUCTS OFFERED 176

11.10.4 KEY DEVELOPMENTS 176

11.10.5 SWOT ANALYSIS 176

11.10.6 KEY STRATEGIES 176

12 APPENDIX
12.1 REFERENCES 177

12.2 RELATED REPORTS 178
回上頁